文献速递消化内镜消化道肿瘤与早癌

第二次息肉切除术后监测结肠镜检查中进展期肿瘤的检出率:系统综述与Meta分析

Yield of Advanced Neoplasia at Second Post-polypectomy Surveillance Colonoscopy: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-06-13

该系统综述与Meta分析纳入11项观察性研究共5912人,评估基线结肠镜与首次监测结果组合对第二次监测时进展期肿瘤检出率的影响。结果显示,基线及首次监测均为进展期肿瘤者第二次监测进展期肿瘤比例为26.1%(95%CI 18.4%-35.5%),而两次均无腺瘤者为4%(95%CI 2.5%-6.5%)。作者认为联合基线及首次监测结果可更准确评估风险。

要点

  • 基线无腺瘤且首次监测无腺瘤者,第二次监测进展期肿瘤比例为4%(95%CI 2.5%-6.5%)。
  • 基线进展期肿瘤且首次监测进展期肿瘤者,第二次监测进展期肿瘤比例为26.1%(95%CI 18.4%-35.5%)。
  • 联合基线及首次监测结果评估风险优于仅用最近一次结肠镜结果。

核心结论

  • 研究结果支持联合基线结肠镜和首次监测结肠镜的结果来评估进展期肿瘤风险,比仅使用最近一次结肠镜结果更准确。

研究设计与样本

  • 系统综述与Meta分析,系统检索截至2024年9月的研究文献数据库,纳入报告基线结肠镜及至少2次监测结肠镜检查肿瘤检出率的研究,最终纳入11项观察性研究共5912人。

主要发现

  • 基线无腺瘤者:首次监测无腺瘤、非进展期肿瘤、进展期肿瘤后,第二次监测进展期肿瘤比例分别为4%(95%CI 2.5%-6.5%)、7.2%(95%CI 5.5%-9.4%)、11.4%(95%CI 7.4%-17.2%)。
  • 基线非进展期肿瘤者:首次监测无腺瘤、非进展期肿瘤、进展期肿瘤后,第二次监测进展期肿瘤比例分别为5.4%(95%CI 3.7%-7.9%)、9.1%(95%CI 6.7%-12.3%)、20.2%(95%CI 15.4%-25.9%)。
  • 基线进展期肿瘤者:首次监测无腺瘤、非进展期肿瘤、进展期肿瘤后,第二次监测进展期肿瘤比例分别为9.1%(95%CI 6.2%-13.0%)、12.8%(95%CI 9.5%-17.0%)、26.1%(95%CI 18.4%-35.5%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Individuals who have had polypectomy and at least one surveillance colonoscopy exam are routinely encountered, but evidence to inform risk for subsequent neoplasia and timing of surveillance is limited. Our aim was to conduct a systematic review and meta-analysis of serial surveillance yield. METHODS: We performed a systematic search of research literature databases through September 2024 and identified studies reporting neoplasia yield at baseline colonoscopy and at least 2 surveillance colonoscopies. Summary estimates of advanced neoplasia rates at second surveillance, according to baseline and first surveillance finding combinations (no adenoma, nonadvanced neoplasia, or advanced neoplasia) were pooled. RESULTS: The pooled analysis included 5912 individuals from 11 observational studies. The proportion with advanced neoplasia at second surveillance among those with baseline no adenoma was 4% (95% confidence interval [CI], 2.5%-6.5%) after no adenoma, 7.2% (95% CI, 5.5%-9.4%) after nonadvanced neoplasia, and 11.4% (95% CI, 7.4%-17.2%) after advanced neoplasia at first surveillance, respectively. The proportion with advanced neoplasia at second surveillance among those with baseline nonadvanced neoplasia was 5.4% (95% CI, 3.7%-7.9%) after no adenoma, 9.1% (95% CI, 6.7%-12.3%) after nonadvanced neoplasia, and 20.2% (95% CI, 15.4%-25.9%) after advanced neoplasia at first surveillance, respectively. The proportion with advanced neoplasia at second surveillance among those with baseline advanced neoplasia was 9.1% (95% CI, 6.2%-13.0%) after no adenoma, 12.8% (95% CI, 9.5%-17.0%) after nonadvanced neoplasia, and 26.1% (95% CI, 18.4%-35.5%) after advanced neoplasia at first surveillance, respectively. CONCLUSIONS: These findings support the concept of using results from both the baseline and first surveillance colonoscopies to provide a more accurate risk estimate than using results of only the most recent colonoscopy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pandita P, Le Y, Trivedi M, et al. Yield of Advanced Neoplasia at Second Post-polypectomy Surveillance Colonoscopy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40518061. doi:10.1016/j.cgh.2025.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。